System for Increasing Patient Access to Eye Exams for Diabetic Retinopathy

增加患者接受糖尿病视网膜病变眼科检查的系统

基本信息

批准号：
8592189
负责人：
Matthew S Muller
金额：
$ 91.52万
依托单位：
AEON IMAGING, LLC
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2016-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8592189
关键词：
Address Adoption Adult Affect Age Agreement American Awareness Blindness Boston Calibration Canada Caring Centers for Disease Control and Prevention (U.S.)Clinic Clinical Collaborations Color Communities Computer software County Data Detection Devices Diabetes Mellitus Diabetic Retinopathy Dilatation - action Early treatment Economics Electronics Epidemic Evaluation Eye Eye diseases Feedback Film Fundus Fundus photography Goals Gold Health Insurance Hospitals Image Imaging Device Indiana Individual Institutes International Internet Knowledge Lasers Lead Legal patent Lesion Light Lighting Low income Managed Care Marketing Measures Medical center Methods Mexico Microprocessor Minority Minority Groups Modeling Monitor Mydriasis Mydriatics Online Systems Ophthalmic examination and evaluation Optometry Patient Care Patients Performance Phase Predictive Value Price Primary Health Care Protocols documentation Provider Public Health Publishing Pupil Quality Control Reader Recommendation Relative (related person)Research Research Infrastructure Retina Retinal Risk Scanning Schools Secure Sensitivity and Specificity Series Site Small Business Innovation Research Grant Solutions System Technology Telemedicine Testing Time Training Underserved Population Universities Validation Vision Visit Wellness Center Work base care systems compliance behavior cost cost effective diabetic diabetic patient digital disorder prevention eye center light scattering new technology novel programs public health relevance quality assurance racial and ethnic screening sensor validation studies willingness

项目摘要

Project Summary / Abstract - EY020017 Phase IIB Competitive Renewal The overall goal of the proposed SBIR program is to implement and evaluate a low cost, portable retinal camera, the DLP-Cam, in a primary care system for diabetic retinopathy (DR) screening. Untreated DR has reached epidemic levels in underserved populations worldwide. To fully address this issue, DR screening must lead seamlessly from a patient's primary care provider to vision-saving treatment and must be widely available to the underserved, for instance within a community clinic setting. Aeon Imaging LLC, in partnership with the Indiana University School of Optometry and the UC Berkeley Optometric Eye Center, is addressing the public health challenge of providing eyecare to the underserved by developing cost-effective DR screening cameras and internet-based telemedicine platforms. In Phase II of EY020017, over 1,900 underserved diabetic patients, of which over 90% were racial/ethnic minorities, were imaged at four Alameda County Medical Center community clinics using Aeon's Laser Scanning Digital Camera (LSDC), and commercial fundus and OCT cameras for comparison. Images and de-identified imaging session data are transferred for review and analysis to Aeon's cloud server and to EyePACS, a web-based teleophthalmology platform developed by UC Berkeley and used in over 190 US and international sites. In this Phase IIB Renewal, Aeon seeks to complete the final steps to successfully commercialize its novel DLP-Cam technology for sustainable DR screening. Aeon's DLP-Cam provides high contrast, confocal views of the retina in natural appearing red/green color images, or monochrome in either red or green, avoiding blue light. No pupil dilation is needed. The compact and lightweight, microprocessor controlled, internet ready DLP- Cam is detachable from a standard slit-lamp style alignment base for ease of transport. The projected price is well below competing products. As in EY020017, data will be automatically encrypted and uploaded to secure servers for review and referral recommendations. Clinical validation of the DLP-Cam will be performed by the Joslin Vision Network (JVN), a leading international diabetes research organization. Aeon will also test the integration of the DLP-Cam into the workflow and managed diabetic patient care at 3 primary care sites, where primary care providers (PCPs) will be trained in the evaluation of retinal images. In this DR screening model, referral decisions are communicated at the time of a patient's visit to increase compliance with recommended eye care. Certified telemedicine image graders provide quality assurance of the screening system, and ongoing image feedback for training. The growing disparity in diabetes-related eye care among minority and underserved populations requires a solution such as the DLP-Cam that effectively screens for eye disease, thus assisting PCPs in providing managed care and promoting awareness among diabetic patients. If successful, the DLP-Cam's adoption by PCPs will enable widespread, efficient, and sustainable DR screening, thereby reducing barriers to eye care.

项目摘要/摘要 - EY020017 IIB 期竞争性更新拟议的 SBIR 计划的总体目标是实施和评估低成本、便携式视网膜 DLP-Cam 相机在初级保健系统中用于糖尿病视网膜病变 (DR) 筛查。未经治疗的 DR 有在全世界服务不足的人群中达到了流行病水平。为了彻底解决这个问题，DR 筛查必须从患者的初级保健提供者到视力挽救治疗的无缝引导，并且必须广泛使用服务不足的人群，例如在社区诊所内。 Aeon Imaging LLC 与印第安纳大学验光学院和加州大学伯克利分校合作验光眼科中心正在解决向服务不足的人群提供眼保健服务的公共卫生挑战开发具有成本效益的 DR 筛查摄像机和基于互联网的远程医疗平台。在第二阶段 EY020017，超过 1,900 名得不到充分服务的糖尿病患者接受了治疗，其中 90% 以上是少数族裔/族裔使用 Aeon 的激光扫描数字技术在四个阿拉米达县医疗中心社区诊所拍摄相机（LSDC），与商用眼底相机和 OCT 相机进行比较。图像和去识别化图像会话数据被传输到 Aeon 的云服务器和基于 Web 的 EyePACS 进行审查和分析远程眼科平台由加州大学伯克利分校开发，在 190 多个美国和国际站点使用。在第二阶段更新中，永旺力求完成最后步骤，以成功将其小说商业化用于可持续 DR 筛查的 DLP-Cam 技术。 Aeon 的 DLP-Cam 提供高对比度、共焦视图自然出现的红/绿彩色图像中的视网膜，或红色或绿色的单色图像，避免蓝色光。不需要散瞳。紧凑、轻便、微处理器控制、互联网就绪的 DLP- 凸轮可从标准裂隙灯式对准底座上拆卸下来，以便于运输。预计价格为远低于竞争产品。与EY020017一样，数据将自动加密并上传以确保安全用于审查和推荐建议的服务器。 DLP-Cam 的临床验证将由领先的 Joslin Vision Network (JVN) 进行国际糖尿病研究组织。 Aeon 还将测试将 DLP-Cam 集成到 3 个初级保健中心的工作流程和管理式糖尿病患者护理，初级保健提供者 (PCP) 将在这些场所接受视网膜图像评估方面的培训。在此 DR 筛查模型中，传达转诊决定在患者就诊时，以提高对推荐的眼部护理的依从性。认证远程医疗图像分级机为筛选系统提供质量保证，并为培训提供持续的图像反馈。少数族裔和服务不足的人群中糖尿病相关眼保健的差距日益扩大，需要 DLP-Cam 等解决方案可有效筛查眼部疾病，从而协助 PCP 提供管理式护理并提高糖尿病患者的认识。如果成功，DLP-Cam 将会被采用 PCP 将实现广泛、高效和可持续的 DR 筛查，从而减少眼部护理的障碍。